Shares of Opexa Therapeutics shot up more than 60 percent this morning--taking a big gain on a relatively modest step forward on its new MS therapy Tovaxin. The developer says that it successfully completed two discussions with regulators on its late-stage study of Tovaxin. "We are very pleased with the outcome of our two recent FDA meetings regarding Tovaxin, the first ever personalized T-cell therapy for MS patients, as we believe we now have a well defined path forward for Phase 3 clinical studies," commented CEO Neil Warma. Story